Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zometa for Prevention of Bone Metastases in Prostate Cancer
NCT00294437Phase 3Terminated
- Sponsor
- Central European Cooperative Oncology Group
- Start
- Dec 2003
- Primary completion
- Dec 2003
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of zoledronic acid in prostate cancer (PCa), sponsored by Central European Cooperative Oncology Group. Started Dec 2003; status: terminated.
02
Drugs
zoledronic acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00294437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00294437.